The future of proteasome inhibitors lies in overcoming current limitations and expanding their therapeutic applications. Advances in molecular biology and drug design are paving the way for more potent and selective inhibitors. Additionally, combining proteasome inhibitors with other treatments, such as immunotherapy, holds promise for enhanced efficacy. Research into the ubiquitin-proteasome system continues to reveal new targets and mechanisms, offering potential for novel therapeutic strategies.
